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P62 and ubiquitin are small regulatory proteins demonstrated to have implications in the
prognosis and survival of various malignancies including: hepatocellular, breast, ovarian,
and some gastrointestinal carcinomas. Several trials studied the link of their activity to the
extrinsic apoptosis pathway and showed that their autophagy modification has a critical
stand point in tumorigenesis.These findings explain their vital role in controlling the process
of cell death and survival. It has been shown recently that p62 and ubiquitin overexpres-
sion in different types of cancers, such as triple negative breast and ovarian cancers, have
directly correlated with incidence of distant metastases. We aim to evaluate p62/ubiquitin
expression in gastrointestinal carcinomas of gastric, colonic, and pancreatic origin, and
correlate with annotated clinicopathologic data. In gastric carcinoma (61), positive p62
nuclear expression was noted in 57% and cytoplasmic in 61%, while positive ubiquitin
was nuclear expressed in 68.8%, and cytoplasmic in 29.5%. In colon carcinoma (45), pos-
itive p62 nuclear expression was noted in 29% and cytoplasmic in 71%, while positive
ubiquitin was nuclear in 58% and cytoplasmic in 44%. In pancreatic cancer (18), positive
p62 nuclear expression was noted in 78% and cytoplasmic in 56%, while positive ubiquitin
was nuclear in 83% and cytoplasmic in 72%. Normal gastric (6), colon (4), and pancreatic (4)
tissues were negative for both P62 and ubiquitin (nuclear and cytoplasmic staining<20%).
Ubiquitin high expression was associated with more lymph node metastases in colon (4.14
vs 1.70, P =0.04), and pancreatic adenocarcinomas (3.07 vs 0.33, P =0.03). Also, ubiqui-
tin high expression was associated with worse pancreatic adenocarcinoma overall survival
(1.37 vs 2.26 mos, P =0.04). In addition, gastric cancer patients with high p62 expression
tend to have more poorly differentiated grade when compared to those with low expres-
sion (21 vs 17, P =0.04) but less lymph node metastases (2.77 vs 5.73, P =0.01). P62
and ubiquitin expression did not correlate with other clinicopathologic parameters in gas-
tric, colon or pancreatic denocarcinomas. The results suggest that p62 and ubiquitin are
highly expressed in gastric, colonic, and pancreatic carcinomas. High ubiquitin expression
was noted to have an impact on number of lymph node metastases in patients with colon
and pancreatic adenocarcinomas, but on overall survival only in patients with pancreatic
adenocarcinoma. Also, P62 high expression is correlated with poor differentiation, but less
lymph node metastases, in gastric carcinoma.
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INTRODUCTION
Ubiquitin is a small regulatory protein that was discovered in
1975 by Goldstein (1). It has been found in almost all eukary-
otic cells. It consists of 76 amino acids and is encoded by
four different genes in the human genome: UBB, UBC, UBA52,
and RPS27A. Critical cellular processes are regulated, in part,
by maintaining the appropriate intracellular levels of proteins
through a balance between protein synthesis and degradation.
The ubiquitin–proteasome pathway is a major pathway for the
targeted degradation of proteins. This pathway involves multi-step
enzymatic reactions catalyzed by a cascade of enzymes that
include: ubiquitin-activating enzyme E1, ubiquitin-conjugating
enzyme E2, and ubiquitin ligase E3 (2). In fact, data shows that
ubiquitin plays a vital role in protein degradation and in many
other cellular functions such as: cell growth, cell cycle regula-
tion, immune system functionality, and DNA repair processes
(3). In addition, it is engaged in the regulation of turnover
as well as the activity of many target proteins involved in cell
www.frontiersin.org March 2015 | Volume 5 | Article 70 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mohamed et al. P62/Ubiquitin expression in gastrointestinal carcinomas
proliferation, differentiation, and cell death (4). Therefore, any
disruption in its pathway is linked to several diseases including:
neurodegenerative diseases, genetic disorders, cancers, and other
immunological disorders.
P62 is an ubiquitin binding protein which induces activation
of multiple upstream signaling pathways, including those trig-
gered by epidermal growth factor (EGF) receptors. In several
studies, immunohistochemical staining of p62 has been shown
in different parts of the gastrointestinal tract (stomach, esopha-
gus, large intestine) including cancers (5, 6). Its expression has
been associated with cell differentiation and tumor metastasis
in different types of malignant tumors (such as breast cancer)
(7). Many trials suggest that this expression of p62 in tissues,
and the appearance of autoantibody to p62, might be related
to manifestations of malignancy (6). The accumulation of p62
is reported to be associated with a higher risk of distant metas-
tases, poorer prognosis (particularly in breast cancer), and to be
predictive of response to clinical treatments (5).
Moreover, regulation of ubiquitin is involved in tumor pro-
gression and oncogenesis. Its overexpression in human cancers
correlates with chemoresistance and poor clinical prognosis (2).
This critical role of ubiquitin in protein turnover in cell cycle reg-
ulation makes this process a target for oncogenic mutations and
codes for several oncogenes in different malignancies (8, 9) such
as colonic and renal cell carcinoma.
In gastrointestinal (GI) carcinomas, there are few studies of
the expression of P62/ubiquitin. It has been shown that ubiquitin
expression in pancreatic adenocarcinoma significantly correlates
with clinical stage, degree of histologic differentiation, lymph node
metastasis, and poor overall survival (10). However, there are little
data about the role of both p62 and ubiquitin in gastric and col-
orectal carcinogenesis, prognosis, and aspects of its inhibition for
therapeutic purposes.
In this study, in order to understand the roles p62/ubiquitin
play in gastrointestinal carcinomas of gastric, colorectal, and pan-
creatic origin, we carried out immunohistochemical analyses of
p62/ubiquitin expression in a cohort of patients with annotated
clinicopathologic data. Expression of both markers was correlated
with clinicopathologic parameters and survival.
DESIGN
STUDY GROUP
The study group was composed of 61 gastric, 45 colon, and 18
pancreatic adenocarcinomas from patients diagnosed at Emory
University Hospital between 2000 and 2013 with tissue avail-
able in tissue microarrays (TMAs). TMAs were constructed using
two 1.0 mm tissue cores from each neoplasm, and included non-
neoplastic tissues. Permission to use the TMAs and to review
pathology reports and patient charts was obtained from the
Institutional Review Board of Emory University.
IMMUNOHISTOCHEMISTRY
Five micron sections of the formalin-fixed, paraffin-embedded
TMAs were tested for the presence of p62 using mouse monoclonal
antibody (SQSTM1) (Abcam, Cambridge, MA, USA) (dilution
1/3200); and ubiquitin using rabbit antihuman polyclonal
antibody (Dako Corp., Carpintaria, CA, USA) (dilution 1/800).
Sections were deparaffinized in xylene and grades of alcohol, then
rehydrated in water. Antigen retrieval was performed in citrate
buffer (pH 6.0) using an electric pressure cooker for 3 min at
12–15 pounds per square inch (120°C), and cooled for 10 min
prior to immunostaining. All slides were loaded on an auto-
mated system (Dako Autostainer) and exposed to 3% H2O2 for
5 min. Tissues were then exposed to primary antibody for 30 min.
Envision plus (Dako) detection system was used, with labeled
polymer-horseradish peroxidase for 30 min, diaminobenzidine as
chromogen for 5 min, and DAKO automation hematoxylin as
counterstain for 15 min.
These incubations were performed at room temperature;
between incubations, sections were washed with Tris-buffered
saline. Cover slipping was performed using the Tissue Tek SCA
(Sakura Finetek USA, Torrance, CA, USA) automatic cover slipper.
Positive controls were hepatocellular carcinoma known to be posi-
tive for p62 and ubiquitin. Negative controls had primary antibody
replaced by buffer.
P62 and ubiquitin expression was nuclear and cytoplasmic.
Intensity was categorized as negative (0), low (1), moderate (2),
and high (3). A staining area of >20% of tumor cells was used
as a cutoff for positivity. The Q-Score, generated by multiplying
the staining intensity by the percent of tumor cell positivity, was
divided into negative (0), low (<100), moderate (100–200), and
high (200–300). Normal gastric, colon, and pancreatic tissues were
included as negative controls.
STATISTICS
After categorizing the subjects into positive and negative groups
based on the 20% cutoff of staining area, the staging of these
three types of cancer was classified into early (stage 0–3A) and
advanced stage (equal or more than stage 3B). The overall sur-
vival time of all the three types of cancer were not normally
distributed and were log-transformed for the following analy-
ses. Chi-square or Fisher’s exact test was used for assessing the
comparability of cancer staging (pathologic stage, tumor size,
lymph node metastases, and distant metastases) between posi-
tive and negative groups. A two-sample t -test was used to evaluate
the association between log-transformed survival time and the
positivity of tumor cells. All the statistical analyses were con-
ducted using SAS statistical software version 9.3 (SAS Institute
Inc., Cary, NC, USA), and P < 0.05 was considered statistically
significant.
RESULTS
Of 124 cases, there were 61 gastric, 45 colorectal, and 18 pan-
creatic carcinoma. Tables 1–3 show the immunohistochemistry
profile for P62 and ubiquitin respectively in the above carcinomas
(Figures 1–4).
In gastric carcinoma (61), immunohistochemical staining
revealed that positive p62 expression was noted [nucleus: 35 (57%)
and cytoplasmic 37 (61%)]. P62 nuclear stain was mostly of mod-
erate to high intensity (2–3), cytoplasmic stain mostly of low to
moderate intensity (1–2). Positive ubiquitin was present [nucleus:
46 (68.6%) and cytoplasmic 18 (30%)]. Ubiquitin nuclear stain
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Table 1 | Analysis of tumor variables and overall survival in patients
with gastric cancer (n=61).
Characteristic Positive Negative P -value*
Age (median/range):
(64/53–84)
Gender
Males, n (%): 42 (69%)
Females, n (%): 19 (31%)
Ubiquitin nucleus
Total number (%) 46/61 (68.6%) 15/61 (24.5%)
Grade 0.81
I n (%) 0 (0%) 1 (6.6%)
II n (%) 12 (26%) 8 (53.3%)
III n (%) 34 (74%) 6 (40.1%)
Tumor size (cm)a,
mean±SD
1.47±0.70 1.30±0.67 0.42
LNS_number, mean±SD 3.39±4.68 6.00±4.00 0.06
Distant mets, n (%) 0.89
Yes 10 (21.74) 3 (20.00)
No 36 (78.26) 12 (80.00)
Stage, n (%) 0.65
Early 27 (72.97) 10 (27.03)
Advanced 18 (78.26) 5 (21.74)
Survival time (months)a,
mean±SD
2.41±1.13 2.66±1.42 0.53
Ubiquitin cytoplasm
Total number (%) 18/61 (30) 43/61 (70)
Grade 0.09
I n (%) 0 (0%) 1 (1.6%)
II n (%) 6 (33.3%) 16 (37.2%)
III n (%) 12 (66.7) 26 (61.2%)
Tumor size (cm)a,
mean±SD
1.52±0.61 1.39±0.73 0.49
LNS_number, mean±SD 4.33±6.17 3.90±3.90 0.75
Distant mets, n (%) 0.14
Yes 6 (33.33) 7 (16.28)
No 12 (66.67) 36 (83.72)
Stage, n (%) 0.37
Early 12 (32.43) 25 (67.57)
Advanced 5 (21.74) 18 (78.26)
Survival time (months)a,
mean±SD
2.68±0.91 2.38±1.30 0.32
P62 nucleus
Total number (%) 35/61 (57) 26/61 (43)
Grade 0.04
I n (%) 1 (2.8) 0 (0)
II n (%) 13 (37.2) 9 (34.7)
III n (%) 21 (60) 17 (65.3)
Tumor size (cm)a,
mean±SD
1.46±0.74 1.39±0.62 0.72
LNS_number, mean±SD 2.77±3.87 5.73±5.08 0.01
Distant mets, n (%) 0.36
Yes 6 (17.14) 7 (26.92)
(Continued)
Characteristic Positive Negative P -value*
No 29 (82.86) 19 (73.08)
Stage, n (%) 0.99
Early 21 (56.76) 16 (43.24)
Advanced 13 (56.52) 10 (43.38)
Survival time (months)a,
mean±SD
2.37±0.19 2.60±1.33 0.48
P62 cytoplasm
Total number (%) 37/61 (61) 24/61 (39)
Grade 0.44
I n (%) 0 (0) 1 (4)
II n (%) 14 (37.8) 8 (33.5)
III n (%) 23 (62.2%) 15 (62.5)
Tumor size (cm)a,
mean±SD
1.35±0.71 1.55±0.65 0.26
LNS_number, mean±SD 4.28±4.36 3.68±5.07 0.62
Distant mets, n (%) 0.09
Yes 5 (13.89) 8 (32.00)
No 31 (86.11) 17 (68.00)
Stage, n (%) 0.52
Early 21 (56.76) 16 (43.24)
Advanced 15 (65.22) 8 (34.78)
Survival time (months)a,
mean±SD
2.47±1.10 2.46±1.36 0.97
*P-values derived from chi-square or Fisher’s exact test for stage categories and
two-sample t-test for log-transformed survival time.
aLog-transformed.
was mostly of moderate to high intensity (2–3), cytoplasmic stain
mostly of low intensity (1).
In colon carcinoma (45), positive p62 expression was noted
[nucleus:13 (29%) and cytoplasmic 32 (71%)]. P62 nuclear and
cytoplasmic stain was mostly of moderate to high intensity (2–3).
Positive ubiquitin was present [nucleus: 26 (58%) and cytoplasmic
20 (44%)], with nuclear stain mostly of moderate to high intensity
(2–3), and cytoplasmic stain mostly of low intensity (1).
In pancreatic carcinoma (18), positive p62 nuclear expres-
sion was noted in 78% (14/18) and cytoplasmic in 56% (10/18).
P62 nuclear stain mostly of high intensity (3), cytoplasmic stain
mostly of moderate to high intensity (2–3). Positive ubiquitin
was nuclear, expressed in 83% (15/18) and cytoplasmic in 72%
(13/18). Ubiquitin nuclear and cytoplasmic stain was mostly of
high intensity (3).
Normal non-neoplastic gastric (6), colon (4), and pancreatic
(4) tissues were negative for both P62 and ubiquitin, nuclear, and
cytoplasmic staining (0–1 intensity,<20%).
Ubiquitin high expression was associated with more lymph
node metastases in colon (4.14 vs 1.70, P = 0.04), and pancre-
atic adenocarcinomas (3.07 vs 0.33, P = 0.03). Also, Ubiquitin
high expression was associated with worse pancreatic adenocar-
cinoma overall survival (1.37 vs 2.26 mos, P = 0.04). In addition,
gastric cancers with high p62 expression were more often poorly
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Table 2 | Multivariate analysis of tumor variables and overall survival
in patients with colon cancer (n=45).
Characteristic Positive,
n (%)
Negative,
n (%)
P -value*
Age (median/range):
(60.6/50–81)
Gender
Males, n (%): 28 (62%)
Females, n (%): 17 (38%)
Ubiquitin nucleus
Total number (%) 26/45 (58) 19/45 (42)
Grade 0.35
I n (%) 0 (0) 1 (5.2)
II n (%) 20 (77) 16 (84.2)
III n (%) 6 (23) 2 (10.5)
Tumor size (cm),
mean±SD
4.68±2.45 4.67±2.09 0.99
LNS_number, mean±SD 2.83±3.96 3.00±4.41 0.90
Distant mets, n (%) 0.07
Yes 5 (16.67) 7 (46.67)
No 25 (83.33) 8 (53.33)
Stage, n (%) 0.14
Early 15 (78.95) 4 (21.05)
Advanced 15 (57.69) 11 (42.31)
Survival time (months)a,
mean±SD
2.67±1.67 2.62±1.77 0.94
Ubiquitin cytoplasm
Total number (%) 20/45 (44) 25/45 (56)
Grade 0.56
I n (%) 0 (0) 1 (4)
II n (%) 16 (80) 21 (84)
III n (%) 4 (20) 3 (12)
Tumor size (cm),
mean±SD
4.98±2.59 4.39±2.03 0.40
LNS_number, mean±SD 4.14±1.85 1.70±0.77 0.04
Distant mets, n (%) 0.44
Yes 7 (31.82) 5 (21.74)
No 15 (68.18) 18 (78.26)
Stage, n (%) 0.86
Early 9 (47.37) 10 (52.63)
Advanced 13 (50.00) 13 (50.00)
Survival time (months)a,
mean±SD
2.40±1.59 2.90±1.77 0.34
P62 nucleus
Total number (%) 13/45 (29) 32/35 (71)
Grade 0.06
I n (%) 0 (0) 1 (3)
II n (%) 11 (84.6) 24 (75)
III n (%) 2 (15.4) 7 (22)
Tumor size (cm),
mean±SD
4.59±2.37 4.72±2.32 0.87
LNS_number, mean±SD 4.27±5.28 2.20±3.18 0.11
Distant mets, n (%) 0.07
(Continued)
Characteristic Positive,
n (%)
Negative,
n (%)
P -value*
Yes 1 (6.67) 11 (36.67)
No 14 (93.33) 19 (63.33)
Stage, n (%) 0.39
Early 5 (26.32) 14 (73.68)
Advanced 10 (38.46) 16 (61.54)
Survival time (months)a,
mean±SD
2.45±1.66 2.76±1.71 0.57
P62 cytoplasm
Total number (%) 32/45 (71) 13/35 (29)
Grade 0.15
I n (%) 1 (3) 0 (0)
II n (%) 25 (78) 12 (92)
III n (%) 6 (19) 1 (8)
Tumor size (cm),
mean±SD
4.67±2.06 4.71±3.17 0.96
LNS_number, mean±SD 3.09±4.38 2.20±2.74 0.55
Distant mets, n (%) 0.28
Yes 8 (22.86) 4 (40.00)
No 27 (77.14) 6 (60.00)
Stage, n (%) 0.87
Early 15 (78.95) 4 (21.05)
Advanced 20 (76.92) 6 (23.08)
Survival time (months)a,
mean±SD
2.66±1.59 2.63±2.05 0.97
*P-values derived from chi-square or Fisher’s exact test for stage categories and
two-sample t-test for log-transformed survival time.
aLog-transformed.
differentiated (21 vs 17, P = 0.04), but less lymph node metas-
tases (2.77 vs 5.73, P = 0.01) when compared to those with low
expression. P62 and ubiquitin expression did not correlate with
other clinicopathologic parameters in gastric, colon, or pancreatic
adenocarcinomas.
DISCUSSION
It has been described before that carcinogenesis is a multi-
step process involving many complex factors (11). Further-
more, genetic mutation in oncogenes, tumor-suppressor genes,
and other tumorigenic factors play an important role in this
process. Recently, there has been growing evidence that a num-
ber of intracellular proteins and auto-antibodies are associ-
ated with increased risk of cancer (12). P62 and ubiquitin
are considered autoantibodies that are found in many malig-
nant tumors (6). Previous studies have demonstrated accumula-
tion of p62/Ubiquitin as cytoplasmic autoantigens in sera from
patients with different types of cancers (13). Their expression
has been reported in the carcinogenesis process (14). Although
reported in some cancers such as hepatocellular carcinoma,
information regarding their expression in other GI tumors is
not studied well. Even now, the association of these regulatory
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Table 3 | Multivariate analysis of tumor variables and overall survival
in patients with pancreatic adenocarcinoma (n=18).
Characteristic Positive,
n (%)
Negative,
n (%)
P -value*
Age (median/range):
64 (50–75)
Gender
Males, n (%): 10 (66.6%)
Females, n (%): 5 (33.3%)
Ubiquitin nucleus
Total number (%) 15/18 (83) 3/18 (17)
Grade 0.22
I n (%) 3 (20) 0 (0)
II n (%) 8 (53) 0 (0)
III n (%) 4 (27) 0 (0)
Tumor size (cm)a,
mean±SD
1.57±1.08 1.93±0.72 0.58
LNS (N, mean±SD) 3.07±4.10 0.33±0.58 0.03
Distant mets, n (%) 1.00
Yes 1 (6.67) 0 (0.00)
No 14 (93.33) 2 (100.00)
Stage, n (%) 1.00
Early 14 (87.50) 2 (12.50)
Advanced 1 (100.00) 0 (0.00)
Overall Survival (months)a,
mean±SD
1.57±1.08 1.93±0.72 0.51
Ubiquitin cytoplasm
Total number (%) 13/18 (72) 5/18 (28)
Grade 0.77
I n (%) 2 (24) 1 (33.3)
II n (%) 7 (58) 1 (33.3)
III n (%) 3 (25) 1 (33.3)
Tumor size (cm)a,
mean±SD
1.14±0.32 1.59±0.73 0.08
LNS_number, mean±SD 2.77±3.61 2.20±4.92 0.79
Distant mets, n (%) 0.61
Yes 0 (0.00) 1 (20.00)
No 13 (100.00) 4 (80.00)
Stage, n (%) 0.29
Early 12 (75.00) 4 (25.00)
Advanced 0 (0.00) 1 (100.00)
Survival time (months)a,
mean±SD
1.37±1.08 2.26±0.51 0.04
P62 nucleus
Total number (%) 14/18 (78) 4/18 (22)
Grade 0.98
I n (%) 3 (23%) 0 (0%)
II n (%) 6 (46%) 2 (100%)
III n (%) 4 (30.7) 0 (0%)
Tumor size (cm)a,
mean±SD
1.25±0.54 1.28±0.29 0.92
LNS_number, mean±SD 2.28±3.65 3.75±4.99 0.52
Distant mets, n (%) 1.00
(Continued)
Characteristic Positive,
n (%)
Negative,
n (%)
P -value*
Yes 1 (7.14) 0 (0.00)
No 13 (92.86) 4 (100.00)
Stage, n (%) 1.00
Early 13 (81.25) 3 (18.75)
Advanced 1 (100.00) 0 (0.00)
Survival time (months)a,
mean±SD
1.72±1.04 1.34±1.02 0.55
P62 cytoplasm
Total number (%) 10/18 (56) 8/18 (44)
Grade 0.31
I n (%) 2 (22) 1 (16.6)
II n (%) 4 (44) 4 (66.6)
III n (%) 3 (33) 1 (16.6)
Tumor size (cm)a,
mean±SD
1.00±0.37 1.52±0.47 0.02
LNS_number, mean±SD 2.00±3.61 3.22±4.24 0.51
Distant mets, n (%) 1.00
Yes 0 (0.00) 1 (11.11)
No 9 (100.00) 8 (88.89)
Stage, n (%) 1.00
Early 8 (50.00) 8 (50.00)
Advanced 0 (0.00) 1 (100.00)
Survival time (months)a,
mean±SD
1.47±1.06 1.77±1.02 0.56
*P-values derived from chi-square or Fisher’s exact test for stage categories and
two-sample t-test for log-transformed survival time.
aLog-transformed.
proteins with the behavior of GI carcinomas is still not fully
understood.
In the current study, the diversity of p62/Ubiquitin expression
was characterized in patients with different digestive system can-
cers. Our data show that p62/ubiquitin are highly expressed in
these GI cancers, and may indicate their role in increased cel-
lular proliferation and promotion of tumorigenesis. However, it
is becoming apparent that p62/ubiquitin influences various cel-
lular processes including cell growth, survival and mitosis; their
role in promoting carcinogenesis is still a gray area. They exhibit
an oncofetal behavior with increased cellular proliferation and
malignant transformation (15). Both p62/ubiquitin have a post-
transcriptional role modulating the stability and function of cer-
tain important mRNAs. They have emerged as crucial molecules in
regulation of autophagy, and as modulators of mitotic transit and
genomic stability allowing tumor cells to survive under conditions
of autophagy defects. In addition, recent studies demonstrated
an unanticipated role for p62 in activation of the mammalian
target of rapamycin (mTOR) pathway; which is a central regu-
lator of cell growth and autophagy, and is aberrantly activated
in many types of cancer such as hepatocellular carcinoma (14,
16). Also, p62 accumulation has been directly correlated with
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FIGURE 1 | Ubiquitin cytoplasmic positive in gastric carcinoma.
FIGURE 2 | Cytoplasmic positive in gastric carcinoma.
higher risk of distant metastasis in triple negative breast carcinoma
patients (5).
Our results confirm the recent growing evidence that a number
of intracellular proteins with RNA-binding motifs have been iden-
tified in human cancers. High ubiquitin expression is associated
with increased frequency of lymph node metastases in both
FIGURE 3 | Ubiquitin cytoplasmic positive in colon carcinoma.
FIGURE 4 | P62 cytoplasmic positive in colon carcinoma.
colon and pancreatic adenocarcinomas, and has an impact on
overall survival in patients with pancreatic adenocarcinoma being
associated with worse overall survival (1.37 vs 2.26 mos,P= 0.04).
High p62 expression is associated with poorly differenti-
ation but less lymph node metastases in gastric carcinoma.
Our study results do not show correlation between P62 and
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ubiquitin expression and other clinicopathologic parameters
in gastric, colon, and pancreatic adenocarcinomas. In pre-
vious studies, p62/ubiquitin overexpression has been associ-
ated with increased incidence of recurrence after treatment,
and decreased overall survival (2, 5). Our data show that
both markers may represent potentially promising therapeutic
targets.
In summary, in our current study we extended immunohis-
tochemical analysis from hepatic to other gastrointestinal car-
cinomas. There was significant expression of p62/ubiquitin in
gastric, pancreatic, and colonic carcinomas. In addition, ubiqui-
tin expression seems to have an impact on frequency of lymph
node metastases in colon and pancreatic carcinomas and overall
survival in patients with pancreatic adenocarcinoma.
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